A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)

Inclusion Criteria: * Patient has a diagnosis of Stage IV pancreatic adenocarcinoma with distant metastases * Patient is scheduled to receive standard chemotherapy containing gemcitabine * Patient has not received prior systemic therapy for advanced pancreatic adenocarcinoma * Patient must be available for periodic blood sampling, study-related assessments, and management at the treating institution Exclusion Criteria: * Patient has had open abdominal surgery within 6 weeks of the screening visit * Patient has had radiotherapy to the thorax, abdomen, or pelvis within 6 months of the screening visit * Patient has an active infection, inflammation, or unresolved bowel obstruction * Patient has poorly controlled diabetes